SCHEDULE: Roche Discloses Freenome Stake

Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd have jointly filed a Schedule 13G, reporting beneficial ownership of 17.4% of Freenome, Inc. common stock.

Summary

• Roche entities (Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd) have filed a joint Schedule 13G.
• This filing reports their beneficial ownership of Freenome, Inc. common stock.
• The total beneficial ownership amounts to 18,692,766 shares.
• This represents 17.4% of Freenome, Inc.'s outstanding common stock as of July 20, 2026.
• The shares are held by Roche Holdings, Inc. (18,055,686 shares) and Roche Finance Ltd (637,080 shares).
• Roche Holding Ltd is the ultimate parent entity.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative disclosure of beneficial ownership rather than a strategic or financial update.

Positives

• Significant stake held by a major healthcare company (Roche) in Freenome, Inc., potentially indicating confidence or strategic interest.
• Clear disclosure of ownership, providing transparency to the market.

Negatives

• The filing is purely an ownership disclosure and does not provide any new financial or operational information about Freenome, Inc.

Risks

• The filing does not contain any specific risk factors related to Freenome, Inc. or the investment itself.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The undersigned acknowledge that each shall be responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein, but shall not be responsible for the completeness or accuracy of the information concerning any other person making the filing, except to the extent that such person knows or has reason to believe that such information is inaccurate.
• It is understood and agreed that the joint filing of this Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, nor as a joint venture for purposes of the Investment Company Act of 1940.

Industry Context

StockSavvy.ai notes that large pharmaceutical and healthcare conglomerates like Roche often take significant stakes in innovative biotechnology companies, reflecting a common strategy of R&D investment and potential future acquisition targets within the life sciences sector.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, which is the required disclosure for passive investors crossing a 5% beneficial ownership threshold. It does not provide performance data for comparison against industry peers or benchmarks.

Stakeholder Impact

• Shareholders of Freenome, Inc.: Increased transparency regarding significant institutional ownership by a major player in the healthcare industry.
• Competitors: Awareness of Roche's substantial investment in Freenome, Inc. may influence competitive strategies.

Next Steps

• Roche entities will continue to monitor their ownership levels in Freenome, Inc. and file amendments to this Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Freenome, Roche, Schedule 13G, Beneficial Ownership, Healthcare, Biotechnology, Investment